EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2026-03-23

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026-03-23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026-02-10

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

2026-01-22

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

2025-12-17

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025-11-21

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025-08-26

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025-08-26

Resilient Interim Results: Essex Bio-Technology Drives Growth and Innovation, Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million, 16.7% Dividend Surge, Continued Innovation Momentum in Regulatory Milestones

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT